Kornimate/medical-research-clean huggingface dataset:
toy hygiene education for hospitalized mothers

Conditions: Children, Only; Educational Problems; Hospital Infection

Summary: the present study aims to evaluate the effectiveness of toy hygiene education given to mothers of hospitalized children on their knowledge and practices, as well as the cleanliness of toy surfaces.

while studies show that toys contain significant amounts of pathogenic microorganisms and may be effective in the spread of hospital-acquired infections, it appears that the literature and hospital practices on the disinfection of these toys are quite limited. additionally, there is no routine practice to ensure toy hygiene in most health institutions. therefore, in order to prevent the transfer of infectious agents through toys, policies and guidelines regarding toy cleaning methods and frequency should be established in hospitals. at the same time, families should be educated about the fact that toys can be a source of infection, and correct behavioral changes regarding toy hygiene should be created. when the literature was examined, it was determined that there were no routine hygiene practices regarding the cleaning of toys in children's clinics in turkey. for this reason, the study will examine the effect of the toy hygiene education created by the researchers on the knowledge levels and practices of mothers and the surface cleaning of toys. it is thought that the results of the study will be a basis for creating clinical guidelines.

Eligibility criteria:
inclusion criteria: * mothers with children in the play (1-3) and preschool (4-6) periods * those who keep toys (plastic, metal, wooden, technological) with their children * mothers who are always with their children as companions * mothers whose children receive inpatient treatment for at least 3 days exclusion criteria: * mother has hearing, vision or mental problems * the mother has been diagnosed with ocd (obsessive compulsive disorder) or has an obsession with cleaning. * not being able to speak turkish * being under 18 years of age * do not place the child in isolation (contact isolation, droplet isolation, respiratory isolation).
aminophylline prophylaxis for postdural puncture headache

Conditions: Postdural Puncture Headache

Summary: postdural puncture headache is a rare but serious complication of spinal anesthesia. many drugs were studied in prevention or treatment of that complication. however, there are limited numbers of trials about intravenous aminophylline for prevention. because of that we retrospectively aimed to investigate the effectiveness of aminophylline for postdural puncture headache in cesarean section.

retrospective trial about the effect of intravenous aminophylline for prevention of pdph after caserean section with spinal anesthesia

Eligibility criteria:
inclusion criteria: * patients aolder than 18 years old exclusion criteria: * conversion to general anesthesia
hemospray in gastrointestinal bleeding: a real-life multicenter cohort

Conditions: Gastrointestinal Hemorrhage; Ulcer Hemorrhage; Tumor Bleeding

Summary: this is an observational, retrospective, analytical, and multicenter study conducted at 17 hospitals. our research aims to assess the effectiveness of hemospray® in patients with gastrointestinal bleeding in clinical practice. besides, we aim to detect predictors of treatment failure defined as unsuccessful immediate hemostasis or rebleeding.


Eligibility criteria:
inclusion criteria: * patients with gastrointestinal bleeding treated with hemospray®. exclusion criteria: * none.

Keywords: hemospray, gastrointestinal bleeding, gastrointestinal hemorrhage, hemostatic powder
study will test the theory that training with the facial-flex exercise device will improve snoring in patients

Conditions: Primary Snoring; Sleep Apnea

Summary: the study will test the hypothesis that training with the facial-flex exercise device for six weeks will improve snoring in patients with primary snoring or very mild sleep apnea.

subjects will be studied before and after 6 weeks of facial-flex training using portable monitoring. there will be 8 patient visits and 2 additional trips to the sleep center to return the portable sleep monitor.

Eligibility criteria:
inclusion criteria: * patients with a history of loud snoring but no observed breathing pauses by bed partner (or only very mild obstructive sleep apnea on a previous sleep study within the prior year) will be enrolled. * very mild sleep apnea is defined here as an apnea-hypopnea index (ahi) \< 10/hour). * this assumes that the ahi is computed using hypopnea defined as a 30% drop in the flow signal associated with a 4% or greater arterial oxygen desaturation. exclusion criteria: * prior upper airway surgery * daytime sleepiness (epworth sleepiness scale \>12/24), (obesity bmi \> 35 kg/m2) * significant arterial oxygen desaturation defined as 5 minutes or more with an arterial oxygen desaturation less than 88% * severe insomnia with less than 4 hours of sleep per night * uncontrolled psychiatric disorder * any disorder causing facial weakness * pregnancy * temporal mandibular joint problems.

Keywords: sleep study snoring sleep apnea muscle laxity oral appliance facial muscles neck muscles upper airway muscle strength dynamic resistance oral exercise facial toning facial muscle strength strap muscles of the neck apnea-hypopnea
using parental involvement during venipuncture to reduce venipuncture pain and anxiety in children with cancer

Conditions: Anxiety; Cancer; Child; Nursing; Pain

Summary: this study aims to determine whether parental involvement during venipuncture reduces venipuncture pain and anxiety in children with cancer.

this was a randomized controlled trial with parallel groups in which 60 children with cancer aged 6-12 were randomly allocated to a control group (n = 30) and a parent involvement group (n = 30). each child's anxiety was evaluated by the child using the children's fear scale before, during venipuncture, and each child's pain during the procedure was evaluated by the child using the wong-baker faces pain rating scale. each child's heart rate and oxygen saturation were measured with a pulse oximeter device before, during the procedure. control group (n = 30): routine venipuncture procedure was applied to the control group. the parent was present in the child's room but did not participate in the procedure. parent involvement group (n = 30): a parent was involved in the procedure. the parent held the children in their arms and holding the extremity from which the blood was drawn, holding the hands of children and communicating with their children in the child's room, and in this way the parent was involved in the procedure.

Eligibility criteria:
inclusion criteria: * diagnosed with cancer, * requiring venipuncture for blood tests, * 6-12 years old, * not having taken any analgesics in the 6 hours before venipuncture, * being in a non-terminal phase of the disease, * absence of neutropenia, * volunteering to participate in the study, * the absence of any health problems that prevent communication in the parent or the child exclusion criteria: * reporting pain for another reason in the time of the venipuncture * having another chronic disease besides cancer
a population-based study of celiac disease in south europe in children between 1 to 5 years of age

Conditions: Celiac Disease

Summary: celiac disease (cd) was diagnosed for years almost exclusively in children. this is due to the fact that in adulthood it manifests in a much more attenuated form, while the classic form with severe diarrhea, malnutrition and dehydration is observed almost exclusively in children. classic studies, carried out prior to the widespread use of serology as a cd diagnostic tool, already showed that there is variability in gluten sensitivity and that in a non-negligible proportion of cases (10%) gluten sensitivity appears to be transient. subsequent studies, including patients diagnosed by serology or population screening studies, suggest that progression to gluten latency or tolerance may occur in a higher proportion of patients, ranging from 20 to 50% depending on the geographical region. in the first decade of the 2000s, the researchers group performed a prevalence observational cross-sectional study survey in catalonia (autonomous region in the northeast of spain) that accurately reflected the distribution of the reference catalan population in terms of sex and age. the results showed a drastic and significant drop in the prevalence of cd disease in relation to age, with the prevalence of cd in children being 5 times higher than adults (1:71 vs. 1:357). strikingly, the reduction in prevalence was especially notable in the first 4 years of life. two possibilities were proposed to explain this unexpected finding in a disease that is lifelong: 1) the existence of an environmental effect (cohort effect) acting as a disease trigger in early childhood during the study period (e.g., bacterial or viral infections, vaccines, food policies related to gluten introduction, use of antibiotics, etc.). 2) the appearance of age-related tolerance to gluten in a proportion of cases. interestingly, it has been suggested that immunological tolerance might be more frequent in children diagnosed with cd before the age of two. the aims of the present epidemiological study are: 1) to determine the prevalence of cd in catalonia in children under 5 years of age and compare it with the results obtained in the previous 2004-2007 study; 2) to investigate the potential effect of environmental factors on disease prevalence; and 3) to evaluate longitudinally the appearance of tolerance to gluten in the cd cases detected. therefore, this study has been designed using exactly the same cd screening methodology and reproducing the reference population in the same geographical area as the previous 2004-2007 study.


Eligibility criteria:
exclusion criteria: * heart failure or unstable cardiopathy * copd or respiratory insufficiency * coagulopathy * hepatic cirrhosis * kidney failure * active neoplasm * gluten-free diet without cd diagnosis

Keywords: celiac disease environmental factors tolerance to gluten
safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures

Conditions: Status Epilepticus

Summary: to evaluate the safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures as part of seizure treatment protocol in pediatric er


Eligibility criteria:
inclusion criteria: * child with clinical presentation of status epilepticus exclusion criteria: * all others
postoperative analgesic efficacy of continuous wound infusion after laparoscopy

Conditions: Benign Gynecologic Neoplasm

Summary: studies evaluating the effectiveness of continuous wound infusion (cwi) to manage postoperative pain following laparoscopy are markedly lacking. especially, there was no study comparing cwi and placebo in treating gynecologic laparoscopy. therefore, the investigators conducted this randomized, double-blind, placebo-controlled trial to investigate whether cwi of local anesthetics was an effective strategy for enhanced recovery after surgery (eras), compared with placebo in patients undergoing benign gynecologic laparoscopy.

laparoscopic surgery has become an acceptable alternative for open surgery in treating benign gynecologic diseases. one of most important advantages of laparoscopy is a reduced postoperative pain compared with open surgery. moreover, postoperative pain plays an important part in the enhanced recovery after surgery (eras) pathway. although the length of hospitalization and recovery period after laparoscopy tends to be shorter, postoperative pain can still be an important issue. recently, continuous wound infusion (cwi) providing a constant flow of local anesthetic directly a surgical wound postoperatively has been widely used to reduce pain after cesarean section and open surgery. studies evaluating the effectiveness of cwi to manage postoperative pain following laparoscopy are markedly lacking. especially, there was no study comparing cwi and placebo in treating gynecologic laparoscopy. therefore, the investigators conducted this randomized, double-blind, placebo-controlled trial to investigate whether cwi of local anesthetics was an effective strategy for eras, compared with placebo in patients undergoing benign gynecologic laparoscopy.

Eligibility criteria:
inclusion criteria: * age between 18 and 80 years, * american society of anesthesiologists physical status (asaps) classification i-ii * the absence of pregnancy at the time of surgery exclusion criteria: * allergy to amide local anesthetics including ropivacaine * laparoscopic surgery needing ≥ 3 separate skin incisions * history of ventral or incisional hernia * pre-existing coagulopathy, neurologic or cognitive dysfunction * systemic or regional (especially, umbilicus) infection * previously taking opioids for acute or chronic pain * inability to accurately express their pain.
correlation between access blood flow and extracorporeal blood flow

Conditions: Arteriovenous Fistula

Summary: the purpose of this study is to determine if effective extracorporeal blood flow(eebf) has correlation with access blood flow (qa), when eebf adjusts with dynamic arterial line pressure (dalp) in patients with arteriovenous fistulae in hemodialysis treatment.

accesses that show a large (\>15%) decrement over time in vascular access blood flow are associated with a high risk of thrombosis. serial measurements of vascular access blood flow predict access thrombosis. at the moment, the measurement of access flow is time consuming, operator dependent, so that it cannot be done with every treatment. we hypothesized that extracorporeal blood flow at pressure of -200 to -260 mmhg in arterial line has correlation with access blood flow and this can be used to estimate access blood flow.

Eligibility criteria:
inclusion criteria: * patients with chronic kidney disease k-digo 5d in hemodialysis treatment) * permanent vascular accesses with native arteriovenous fistulas (avf) * avf that were at least 12 weeks old exclusion criteria: * inflammation and pain in avf * negation to participate in the study

Keywords: arteriovenous fistula access blood flow extracorporeal blood flow dynamic arterial line pressure hemodialysis treatment
study of the tolerability, safety, pharmacokinetics and pharmacodynamics of alirocumab sar236553 (regn727)

Conditions: Hypercholesterolemia

Summary: primary objective: injection site tolerability secondary objective: * to assess the safety profile of alirocumab sar236553 (regn727) * to assess the pharmacokinetic-pharmacodynamic relationship of alirocumab sar236553 (regn727)

the total duration of study for each subject is up to 15 weeks including a screening period up to 3 weeks.

Eligibility criteria:
inclusion criteria: * serum ldl-c levels\>100 mg/dl at screening visit. * male or female subject, between 18 and 65 years inclusive. * body weight between 50.0 and 95.0 kg inclusive if male, between 40.0 kg and 85.0 kg inclusive if female, body mass index (bmi) between 18.0 and 30.0 kg/m² inclusive. * certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination). * normal vital signs after 10 minutes resting in supine position. * normal standard 12-lead ecg after 10 minutes resting in supine position. * laboratory parameters within the normal range, unless the investigator considers an abnormality to be clinically irrelevant for healthy subjects. * if female, subject must use a double contraception method, except if she is sterilized for more than 3 months or postmenopausal. exclusion criteria: * subjects indicated for the use of statins according to criteria in national cholesterol education program adult treatment panel iii guidelines, as updated in 2004 (see appendix c). * initiation of a new diet or major change to a previous diet within 4 weeks prior to screening (day -21 to -2). subjects must be willing to maintain a consistent diet for the duration of the study. * use of a medication or nutraceutical in order to alter serum lipids within 4 weeks prior to screening (day -21 to -2), including but not limited to statins, ezetimibe, fibrates, niacin, or omega-3 fatty acids, bile acid resins. * fasting serum triglycerides \>200 mg/dl measured after an 8 to 12 hour fast. * history of a hypersensitivity reaction to doxycycline or similar compound. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
using of bone marrow stem cell concentrate with platelet rich fibrin and bone graft in bone reconstruction of upper jaw bony cystic defects, comparing with platelet rich fibrin with bone graft

Conditions: Maxillary Cyst

Summary: will the use of bone marrow stem cells with platelet rich fibrin enhance and accelerate the bone regeneration in the upper jaw cystic defects ?

reconstruction of critical size bone defect in maxillofacial surgery is a great challenge, current practice of bone reconstruction still having problems like delay in bone regeneration (up to 12 months) and bone graft failure and low availability of autogenous bone graft. last decade stem cells therapy gained great interest, in many studies bone marrow stem cells showed promising result in bone regeneration enhancing . platelet rich fibrin prf also capability of enhancing bone and tissue regeneration by releasing of certain protein molecules call growth factors that initiate sequential biological events resulting in stem cells migration into the site of bone defect and differentiation to bone formation cells (osteoblast cells ).

Eligibility criteria:
inclusion criteria: * age range 18-50 years * patients with a critical size maxillary cyst. (\>3 cm) * patients that free of any significant medical conditions that could affect healing or outcomes. exclusion criteria: * patients with large jaw cyst that endanger vital structures * patients with significant medical condition * age under 18 years

Keywords: maxillary cyst bone marrow stem cells platelet rich fibrin prf bone graft bone reconstruction jaw cyst
sufentanil nanotab pca system/15 mcg for acute post-operative pain in vertebral surgery: a preliminary investigation

Conditions: Postoperative Pain; Spinal Fusion; Spondylolisthesis, Lumbar Region; Sufentanil

Summary: the zalviso® sufentanil sublingual tablet system (ssts) (grünenthal italia, milan, italy) is a patient-controlled analgesia (pca) system approved in september 2015 by the european commission for the management of acute moderate-to-severe pain in adult patients in a hospital setting. this preprogrammed drug/device combination product delivers a fixed dose of 15 mcg of sufentanil tablets as needed, in a non-invasive sublingual dosage form. multimodal analgesia is defined as the administration, by one or more routes, of various analgesic medications with different mechanisms of action, thereby providing superior analgesia with fewer side effects. to improve pain control and patient satisfaction, patient-controlled analgesia (pca) techniques have been developed, i.e. any delivery system which allows patients to self administer predetermined doses of analgesic drug to relieve pain. over the past decades, intravenous (iv) pca with morphine has been the gold standard for acute pain control. in our clinical practice, though, not only iv-pca pumps were frequently prone to technical problems, but also patients and caregivers were not often able to understand or activate them, thus raising important safety issues and profoundly affecting the management of pain control. as a consequence, iv-pca eventually fell into disuse, although no alternative has emerged until recently. the ssts should go beyond the above-quoted limitations: it is a non invasive, patient-controlled and easy to use device, with an effective and safe opioid profile. it is, in our thinking, a promising technology. the aim of this retrospective analysis is to examine the role of the ssts for management of pain after vertebral surgery, as part of a multimodal approach.


Eligibility criteria:
inclusion criteria: * patients who underwent elective open lumbar arthrodesis surgery (either by an anterior or posterior approach) in degenerative lumbar spine conditions who were between 18 and 75 years old and post-operatively treated with sufentanil nanotab pca system as part of a multimodal analgesic regimen. * general anesthesia was performed. perioperative regional anesthetic techniques and local anesthetic wound infiltration in the operating room were not performed. exclusion criteria: * patients who refused to participate in the study.
codeine in mechanically ventilated neonates

Conditions: Mechanically Ventilated Neonates; Painful Procedures in Newborns

Summary: the purpose of this study is to determine the absorption and bioavailability of codeine in relation to postnatal (pna) and postconceptional (pca) age; determine the parent drug (codeine), its active metabolites, their formation rates and their ratios in relation with pca and pna; and identify relevant genetic polymorphisms of opioid metabolism in the study population and their potential relationship to the biodisposition and pharmacodynamic effects of codeine. the study population is intubated and mechanically ventilated infants equal to or greater than 26 weeks gestational age at birth and less than 4 weeks postnatal age.

this proposal has its origins in a larger initiative to elucidate the pharmacological basis for the interindividual differences observed in opioid responsiveness. gaps in our knowledge related to opioid disposition in newborns need to be addressed to complete the design of the required overarching initiative in which age could be treated as a continuous variable within a context of pk, pd and pg determinants.this proposal is designed to generate preliminary data that addresses two issues. first, can newborns absorb enterally administered codeine and is this ability determined by pca or pna age? the second relates to the ability of newborn infants to catalyze those reactions required to metabolically activate both codeine and morphine. the latter will also be evaluated within the context of pca versus pna age. these data will not only fill an information gap that must be addressed before the larger initiative moves forward, but they also provide a platform for serious study of the ontogeny of certain pharmacokinetic processes that may prove critical to our understanding of newborn drug disposition. in this way, codeine can provide important insights concerning the ontogeny of drug disposition and permit the determination of the relative importance of pca versus pna ages to the functional expression of these processes.

Eligibility criteria:
inclusion criteria: * neonates ≥ 26 weeks pca receiving mechanical ventilation and painful procedure will be eligible for participation in the study * subject's parent/legal guardian must give written informed consent prior to study participation * subject is receiving opioid analgesia therapy based on caregiver determination. the ideal patient will not be receiving morphine. * must be able to receive an enteral dose of codeine. exclusion criteria: * known hypersensitivity to morphine, fentanyl, or codeine * patients with alt concentrations \>2x upper limit of normal for age or clinical evidence of hepatic failure * patients with serum creatinine concentrations \>2x upper limit of normal for age or clinical evidence of renal failure * patients who are npo * babies born to maternal drug abuse. * total serum bilirubin level of \> 10 mg/dl or 170 umol/l.

Keywords: codeine, neonates, pediatric pharmacology